Business Context and Reporting Period
Sunshine Biopharma Inc., an emerging growth company incorporated in Colorado, filed this Form 8-K on January 4, 2018, reporting events occurring on January 1, 2018. The company is headquartered in Pointe-Claire, Quebec, Canada.
Key Financial Metrics and Transaction Details
The filing details the acquisition of Atlas Pharma Inc. ("Atlas") for a total purchase price of $848,000 (Canadian dollars). The consideration structure includes:
- Cash Payment: $100,500
- Equity Issuance: 20,000,000 shares of Sunshine Biopharma Common Stock
- Promissory Note: $450,000 principal amount with 3% annual interest
Repayment terms for the promissory note require quarterly payments of $10,000 through December 31, 2023. Atlas, a certified chemical analysis company, reported approximately $500,000 in revenue for 2017 and employs 9 full-time staff.
Material Changes
The primary material change is the entry into a definitive Share Purchase Agreement to acquire 100% of Atlas Pharma Inc. This transaction expands Sunshine Biopharma's operational footprint into pharmaceutical and industrial sample chemical analysis. The filing does not provide comparative financial metrics for Sunshine Biopharma itself for the prior period.
Outlook, Risks, and Management Commentary
Management intends to expand Atlas's operations by purchasing additional equipment and hiring technical and sales personnel. However, the filing explicitly states there are no assurances that these expansion plans will occur. Audited financial statements for Atlas are not included in this report but will be filed in a subsequent amendment.
Investor Verification Checklist
- Verify the fair market value of the 20,000,000 common shares issued as part of the consideration.
- Review the upcoming amendment to this 8-K for the audited financial statements of Atlas Pharma Inc.
- Confirm the impact of the $450,000 promissory note on the company's future liquidity and debt covenants.
- Assess the integration risks associated with the planned expansion of Atlas's operations.